MAP2K1 (also called MEK1) and EGFR were validated as negative regulators by showing that treatment of several cancer cell lines with inhibitors of either enzyme increased mRNA levels and cell surface expression of HLA-A and B2m (36). This evidence concerns the gene B2M and cancer.